Grace E. Marx

Centers for Disease Control and Prevention

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Thomas D. Filardo

Centers for Disease Control and Prevention

Caroline J. Waddell

Office of Readiness and Response

Namrata Prasad

Epidemic Intelligence Service

Sarah M. Labuda

Centers for Disease Control and Prevention

Janet M. McNicholl

Computer Emergency Response Team

Julia Janssen

Centers for Disease Control and Prevention

Sapna Bamrah Morris

Centers for Disease Control and Prevention

Ellen Kitchell

Parkland Health & Hospital System

Elliot Raizes

Regions Hospital

Michael Fischer

Computer Emergency Response Team

Cooperative Institutions

Computer Emergency Response Team

Centers for Disease Control and Prevention

National Center for Emerging and Zoonotic Infectious Diseases

Epidemic Intelligence Service

Emory University

Center for Surveillance, Epidemiology, and Laboratory Services

AID Atlanta

Baylor College of Medicine

CDC Foundation

National Center for Immunization and Respiratory Diseases

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022

MMWR Morbidity and Mortality Weekly Report (2022)

Maureen J. Miller Shama Cash‐Goldwasser Grace E. Marx Caroline A. Schrodt Anne Kimball

¶ A list of severe manifestations of monkeypox can be found at https://emergency

Monkeypox

10.15585/mmwr.mm7144e1

Cite

Citations (164)

Mpox vaccine acceptability among people experiencing homelessness in San Francisco — October–November 2022

Vaccine (2023)

Thomas D. Filardo Namrata Prasad Caroline J. Waddell Neela Persad Gerald J. Pellegrini

Mpox has affected many communities in the United States (U.S.), including people experiencing homelessness (PEH). Mpox vaccination has been an important tool to disrupt transmission and protect communities at risk of infection. To better understand mpox vaccine knowledge and attitudes, we surveyed 273 PEH and people accessing homeless service sites in San Francisco. Among 64 participants previously offered mpox vaccination, 38 (59 %) had received the vaccine. Among 209 participants not previously offered mpox vaccination, 108 (52 %) reported they would receive the vaccine. Vaccine acceptance was higher among transgender female participants and among male participants who reported male sex partner preference (MSM). Half of participants who declined vaccination identified that perception of personal risk and vaccine education may increase their likelihood of receiving an mpox vaccine. Leveraging trusted information sources to provide risk communication and vaccine education may increase vaccine uptake among PEH.

10.1016/j.vaccine.2023.07.068

Cite

Citations (6)

Ocular Monkeypox — United States, July–September 2022

MMWR Morbidity and Mortality Weekly Report (2022)

Shama Cash‐Goldwasser Sarah M. Labuda David W. McCormick Agam K. Rao Andrea M. McCollum

As of October 11, 2022, a total of 26,577 monkeypox cases had been reported in the United States.* Although most cases of monkeypox are self-limited, lesions that involve anatomically vulnerable sites can cause complications. Ocular monkeypox can occur when Monkeypox virus (MPXV) is introduced into the eye (e.g., from autoinoculation), potentially causing conjunctivitis, blepharitis, keratitis, and loss of vision (1). This report describes five patients who acquired ocular monkeypox during July-September 2022. All patients received treatment with tecovirimat (Tpoxx)†; four also received topical trifluridine (Viroptic).§ Two patients had HIV-associated immunocompromise and experienced delays between clinical presentation with monkeypox and initiation of monkeypox-directed treatment. Four patients were hospitalized, and one experienced marked vision impairment. To decrease the risk for autoinoculation, persons with monkeypox should be advised to practice hand hygiene and to avoid touching their eyes, which includes refraining from using contact lenses (2). Health care providers and public health practitioners should be aware that ocular monkeypox, although rare, is a sight-threatening condition. Patients with signs and symptoms compatible with ocular monkeypox should be considered for urgent ophthalmologic evaluation and initiation of monkeypox-directed treatment. Public health officials should be promptly notified of cases of ocular monkeypox. Increased clinician awareness of ocular monkeypox and of approaches to prevention, diagnosis, and treatment might reduce associated morbidity.

Monkeypox

10.15585/mmwr.mm7142e1

Cite

Citations (76)

Considerations for Defining Homelessness in Public Health Data Collection

Public Health Reports (2023)

Ashley A. Meehan Caroline J. Waddell Grace E. Marx Kristie E.N. Clarke Anna Bratcher

10.1177/00333549231215850

Cite

Citations (1)

Possible Undetected Mpox Infection Among Persons Accessing Homeless Services and Staying in Encampments — San Francisco, California, October–November 2022

MMWR Morbidity and Mortality Weekly Report (2023)

Caroline J. Waddell Thomas D. Filardo Namrata Prasad Gerald J. Pellegrini Neela Persad

Monkeypox (mpox) is a disease caused by an Orthopoxvirus. The 2022 multinational outbreak, which began in May 2022, has spread primarily by close skin-to-skin contact, including through sexual contact. Persons experiencing homelessness have been disproportionately affected by severe mpox (1). However, mpox prevalence and transmission pathways among persons experiencing homelessness are not known, and persons experiencing homelessness have not been specifically recommended to receive mpox vaccine during the 2022 outbreak (2,3). During October 25-November 3, 2022, a CDC field team conducted an orthopoxvirus seroprevalence survey among persons accessing homeless services or staying in encampments, shelters, or permanent supportive housing in San Francisco, California that had noted at least one case of mpox or served populations at risk. During field team visits to 16 unique sites, 209 participants completed a 15-minute survey and provided a blood specimen. Among 80 participants aged <50 years who did not report smallpox or mpox vaccination or previous mpox infection, two (2.5%) had detectable antiorthopoxvirus immunoglobulin (Ig) G antibody. Among 73 participants who did not report mpox vaccination or previous mpox infection and who were tested for IgM, one (1.4%) had detectable antiorthopoxvirus IgM. Together, these results suggest that three possible undetected mpox infections occurred among a sample of persons experiencing homelessness, highlighting the need to ensure that community outreach and prevention interventions, such as vaccination, are accessible to this population.

Monkeypox

Seroprevalence

10.15585/mmwr.mm7209a3

Cite

Citations (12)